Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04767035 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine
A Phase 1 study of Procedural Sedation, sponsored by Melt Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04767035: Completed Phase 1 study of Procedural Sedation, sponsored by Melt Pharmaceuticals.
NCT04767035 is a Phase 1 study of Procedural Sedation that has completed, run by Melt Pharmaceuticals. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04767035, a Phase 1 study of Procedural Sedation, has completed, sponsored by Melt Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers
Primary Outcome
Maximum Concentration
Conditions Studied
Interventions
- DRUG midazolam / ketamine sublingual tablet
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-01-14 |
| Phase | Phase 1 |
What the finished NCT04767035 record still lists
NCT04767035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Procedural Sedation appearing as the primary indexed condition, and to 1 intervention - of which midazolam / ketamine sublingual tablet is the first listed.
NCT04767035 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04767035 about?
NCT04767035 is a clinical study titled "Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine". A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers
What is the current status of trial NCT04767035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-12-01. Estimated completion is 2021-01-14.
What conditions does trial NCT04767035 study?
This clinical trial studies the following conditions: Procedural Sedation.
What interventions are being tested in trial NCT04767035?
The interventions under investigation include: midazolam / ketamine sublingual tablet (DRUG).
Who is sponsoring clinical trial NCT04767035?
This trial is sponsored by Melt Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04767035 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Procedural Sedation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04767035's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI